Leyden Labs Secures €30M for Groundbreaking Respiratory Nasal Spray
October 18, 2025, 3:39 pm
Leyden Laboratories, a Dutch biotechnology pioneer, recently secured a significant €30 million in equity funding. The European Innovation Council (EIC) Fund and Invest-NL spearheaded this investment. This crucial capital injection will propel the clinical development of PanFlu, Leyden Labs' flagship pan-influenza nasal spray. This innovative solution utilizes broadly protective antibodies. It delivers immediate, localized defense directly to the respiratory mucosa. The spray aims to block airborne respiratory viruses, including influenza and coronaviruses, at their primary entry point. This groundbreaking technology promises broad protection, even for vulnerable populations like the elderly and immunocompromised. The funding underscores Europe's commitment to bolstering pandemic preparedness and regional health innovation. Leyden Labs continues to expand its Mucosal Protection Platform. Its mission: redefine global respiratory disease prevention. This investment marks a critical step in addressing future health crises proactively.
Leyden Laboratories, a biotechnology innovator based in Leiden, Netherlands, has secured €30 million in new equity financing. This substantial funding round was led by the European Innovation Council (EIC) Fund and Invest-NL. The capital infusion marks a significant milestone for the Dutch biotech firm. It accelerates the development of critical respiratory health solutions.
The company intends to deploy these funds strategically. A primary focus is advancing clinical development for PanFlu. This pan-influenza nasal spray represents a core product. The investment also supports Leyden Labs' broader mucosal pipeline. It strengthens platform activities essential for future innovations.
Leyden Labs is pioneering a novel approach to combat airborne respiratory viruses. Its technology centers on antibody-based nasal sprays. These sprays block viruses at their point of entry. The respiratory tract serves as the primary gateway for infection. Stopping viruses here offers immediate defense.
The mechanism is sophisticated yet direct. The sprays deliver broadly protective antibodies. These antibodies go straight to the respiratory mucosa. This localized delivery provides rapid, effective protection. It prevents viral entry and subsequent infection. This differs from traditional systemic immune responses.
PanFlu, Leyden Labs' lead product, embodies this innovative strategy. It utilizes CR9114. This is a human monoclonal antibody. CR9114 is remarkable for its broad recognition capabilities. It identifies a wide diversity of influenza strains. This includes strains that have not yet emerged.
CR9114 targets highly conserved regions of the virus. These regions are less prone to mutation. This inherent stability ensures the therapy remains effective. It protects against future mutations. It offers a robust defense against evolving influenza threats. Such resilience is vital for pandemic preparedness.
The potential impact extends widely. This antibody-based nasal spray offers protection to everyone. It particularly benefits those with weakened immune systems. Immunocompromised individuals often struggle with vaccine efficacy. Elderly populations also face heightened risks. Leyden Labs’ approach provides an immediate shield.
Founded in 2020, Leyden Labs has rapidly established itself. The company's vision addresses a critical global health need. Respiratory viruses pose constant threats. Both seasonal outbreaks and potential pandemics demand innovative solutions. Leyden Labs aims to provide such solutions.
This latest €30 million financing round follows significant prior momentum. Earlier in January 2025, Leyden Labs closed a $70 million Series B round. This demonstrated strong investor confidence. A €20 million venture debt investment also bolstered the company's finances. The European Investment Bank (EIB) provided this. The European Commission’s InvestEU initiative supported it through HERA.
Leyden Labs now boasts a robust global investor base. Key backers include GV (formerly Google Ventures) and Casdin Capital. F-Prime Capital, ClavystBio, and SoftBank Vision Fund 2 are also significant investors. This diverse syndicate underscores the international recognition of Leyden Labs’ mission.
The new funding from the EIC Fund and Invest-NL carries strategic importance. It reinforces Europe’s broader strategy. This strategy focuses on bolstering pandemic preparedness. It aims to enhance health innovation capacity across the continent. Regional autonomy in life sciences is a key objective.
Europe views Leyden Labs' preventive nasal spray as a vital asset. Its ease of use and protective capabilities are highly valued. Safeguarding vulnerable populations is a primary concern. Strengthening Europe's health resilience benefits all member states. This investment reflects that commitment.
Leyden Labs continues to expand its research. Its clinical programs are growing. The Mucosal Protection Platform remains central to its efforts. The company is actively exploring new applications. It aims to apply its core technology against other respiratory pathogens. Coronaviruses represent a significant target.
The company’s headquarters are in Leiden, Netherlands. From this base, Leyden Labs is building a global impact. Its mission is clear: protect populations from respiratory threats. This includes both seasonal influenza and emergent pandemic risks. The company stands at the forefront of this critical fight.
This investment accelerates the journey toward widespread availability. It enables crucial clinical trials. It propels Leyden Labs closer to commercializing its products. A new era of proactive respiratory virus prevention is on the horizon. Leyden Labs is leading the charge.
Leyden Laboratories, a biotechnology innovator based in Leiden, Netherlands, has secured €30 million in new equity financing. This substantial funding round was led by the European Innovation Council (EIC) Fund and Invest-NL. The capital infusion marks a significant milestone for the Dutch biotech firm. It accelerates the development of critical respiratory health solutions.
The company intends to deploy these funds strategically. A primary focus is advancing clinical development for PanFlu. This pan-influenza nasal spray represents a core product. The investment also supports Leyden Labs' broader mucosal pipeline. It strengthens platform activities essential for future innovations.
Leyden Labs is pioneering a novel approach to combat airborne respiratory viruses. Its technology centers on antibody-based nasal sprays. These sprays block viruses at their point of entry. The respiratory tract serves as the primary gateway for infection. Stopping viruses here offers immediate defense.
The mechanism is sophisticated yet direct. The sprays deliver broadly protective antibodies. These antibodies go straight to the respiratory mucosa. This localized delivery provides rapid, effective protection. It prevents viral entry and subsequent infection. This differs from traditional systemic immune responses.
PanFlu, Leyden Labs' lead product, embodies this innovative strategy. It utilizes CR9114. This is a human monoclonal antibody. CR9114 is remarkable for its broad recognition capabilities. It identifies a wide diversity of influenza strains. This includes strains that have not yet emerged.
CR9114 targets highly conserved regions of the virus. These regions are less prone to mutation. This inherent stability ensures the therapy remains effective. It protects against future mutations. It offers a robust defense against evolving influenza threats. Such resilience is vital for pandemic preparedness.
The potential impact extends widely. This antibody-based nasal spray offers protection to everyone. It particularly benefits those with weakened immune systems. Immunocompromised individuals often struggle with vaccine efficacy. Elderly populations also face heightened risks. Leyden Labs’ approach provides an immediate shield.
Founded in 2020, Leyden Labs has rapidly established itself. The company's vision addresses a critical global health need. Respiratory viruses pose constant threats. Both seasonal outbreaks and potential pandemics demand innovative solutions. Leyden Labs aims to provide such solutions.
This latest €30 million financing round follows significant prior momentum. Earlier in January 2025, Leyden Labs closed a $70 million Series B round. This demonstrated strong investor confidence. A €20 million venture debt investment also bolstered the company's finances. The European Investment Bank (EIB) provided this. The European Commission’s InvestEU initiative supported it through HERA.
Leyden Labs now boasts a robust global investor base. Key backers include GV (formerly Google Ventures) and Casdin Capital. F-Prime Capital, ClavystBio, and SoftBank Vision Fund 2 are also significant investors. This diverse syndicate underscores the international recognition of Leyden Labs’ mission.
The new funding from the EIC Fund and Invest-NL carries strategic importance. It reinforces Europe’s broader strategy. This strategy focuses on bolstering pandemic preparedness. It aims to enhance health innovation capacity across the continent. Regional autonomy in life sciences is a key objective.
Europe views Leyden Labs' preventive nasal spray as a vital asset. Its ease of use and protective capabilities are highly valued. Safeguarding vulnerable populations is a primary concern. Strengthening Europe's health resilience benefits all member states. This investment reflects that commitment.
Leyden Labs continues to expand its research. Its clinical programs are growing. The Mucosal Protection Platform remains central to its efforts. The company is actively exploring new applications. It aims to apply its core technology against other respiratory pathogens. Coronaviruses represent a significant target.
The company’s headquarters are in Leiden, Netherlands. From this base, Leyden Labs is building a global impact. Its mission is clear: protect populations from respiratory threats. This includes both seasonal influenza and emergent pandemic risks. The company stands at the forefront of this critical fight.
This investment accelerates the journey toward widespread availability. It enables crucial clinical trials. It propels Leyden Labs closer to commercializing its products. A new era of proactive respiratory virus prevention is on the horizon. Leyden Labs is leading the charge.